xBiotech USA, Inc.

115 articles about xBiotech USA, Inc.

• XBiotech USA, Inc. Halts Cancer Study On Positive Phase 3 Results

  9/2/2014

• XBiotech USA, Inc. Enrolls First Patient In Phase III European Registration Study Using Xilonix™ For Treatment Of Colorectal Cancer

  8/4/2014

• XBiotech USA, Inc. Announces Phase I/II Study Results In Lancet

  4/17/2014

• XBiotech USA, Inc. Welcomes Addition Of Senior Vice President Corporate Development & General Counsel

  4/16/2014

• XBiotech USA, Inc. Issued Patent For Antibody Therapy To Treat Chronic Sterile Inflammatory Diseases

  3/12/2014

• XBiotech USA, Inc. And European Medicines Agency Agree On Phase III Registration Study For Treatment Of Colorectal Cancer

  1/30/2014

• XBiotech USA, Inc. Announces Launch Of Study To Treat Pyoderma Gangrenosum (PG)

  1/17/2014

• XBiotech USA, Inc. Announces Addition to its Board of Directors

  8/30/2013

• XBiotech USA, Inc. Announces Results for Its XILONIX&#0153 Treatment of Non-Small Cell Lung Cancer (NSCLC)

  5/16/2013

• XBiotech USA, Inc. to Present at UBS Global Healthcare Conference

  5/2/2013

• XBiotech USA, Inc. Touts Positive Phase 2 Vascular Disease Results

  11/21/2012

• XBiotech USA, Inc. Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study

  10/29/2012

• XBiotech USA, Inc. Announces Progress in Clinical Development of Treatment for Psoriasis

  10/18/2012

• XBiotech USA, Inc. Eyes $200 Million Campus in E. Austin, Can Potentially Employ Up to 2,000

  8/30/2012

• C3i Inc. to Provide Full-Service Technology Support and Oracle Clinical, Oracle Remote Data Capture Business Process Outsourcing to XBiotech, Inc.

  6/3/2011